LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Lista de Ações・Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Co Ltd ADR

Fechado

SetorSaúde

15.44 2.86

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

15.02

Máximo

15.49

Indicadores-chave
By Trading Economics
Rendimento	-130B -25B
Vendas	-99B 1.1T
P/E Médio do Setor	39.974 49.888
EPS	0.21
Rendimento de Dividendos	4.35
Margem de lucro	-2.222
Funcionários	47,455
EBITDA	-242B 214B

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+39.72% upside

Dividendos
By Dow Jones
Rendimento de Dividendos Médio do Setor	4.35% 2.38%

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-3.7B 48B
Abertura anterior	12.58
Fecho anterior	15.44

Sentimento de Notícias

By Acuity

100%

325 / 344 Ranking em Healthcare

Takeda Pharmaceutical Co Ltd ADR Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

13 de mai. de 2026, 08:59 UTC

Ganhos

Takeda Pharmaceutical Narrows Quarterly Loss, Guides for Lower Annual Profit

29 de jan. de 2026, 07:11 UTC

Ganhos

Takeda Posts Sharply Higher Quarterly Profit, Raises Annual Guidance

19 de dez. de 2025, 03:32 UTC

Grandes Movimentos do Mercado

Takeda Pharmaceuticals Shares Rise on Positive Psoriasis Treatment Results

30 de out. de 2025, 09:39 UTC

Ganhos

Takeda Swings to Loss on Impairment Charges, Cuts Guidance -- Update

30 de out. de 2025, 07:32 UTC

Ganhos

Takeda Posts Quarterly Net Loss, Cuts Guidance

13 de mai. de 2026, 06:57 UTC

Ganhos

Takeda Pharmaceutical 4Q Rev Y1.094T Vs. Y1.053T >4502.TO

13 de mai. de 2026, 06:54 UTC

Ganhos

Takeda Pharmaceutical 4Q Loss Y24.32B Vs. Loss Y103.2B >4502.TO

13 de mai. de 2026, 06:44 UTC

Ganhos

Takeda Pharmaceutical: FY Revenue Declined Mainly Due to Continued Generic Erosion in Neuroscience Segment >4502.TO

13 de mai. de 2026, 06:38 UTC

Ganhos

Takeda Pharmaceutical FY Net Beat Market Consensus >4502.TO

13 de mai. de 2026, 06:31 UTC

Ganhos

Takeda Pharmaceutical FY EPS Y121.75 Vs EPS Y68.36

13 de mai. de 2026, 06:31 UTC

Ganhos

Takeda Pharmaceutical FY Net Y191.76B Vs Net Y107.93B

13 de mai. de 2026, 06:31 UTC

Ganhos

Takeda Pharmaceutical FY Rev Y4.51T Vs Y4.58T

13 de mai. de 2026, 06:31 UTC

Ganhos

Takeda Pharmaceutical FY Pretax Pft Y260.19B Vs Pft Y175.08B

13 de mai. de 2026, 06:31 UTC

Ganhos

Takeda Pharmaceutical FY Net Y191.76B Vs Net Y107.93B

13 de mai. de 2026, 06:31 UTC

Ganhos

Takeda Pharmaceutical FY Oper Pft Y408.76B Vs Pft Y342.59B

29 de jan. de 2026, 06:53 UTC

Ganhos

Takeda Says Higher FY Revenue Forecast Due to Weaker Yen

29 de jan. de 2026, 06:36 UTC

Ganhos

Takeda Raises FY Revenue, Net-Profit Views

29 de jan. de 2026, 06:34 UTC

Ganhos

Takeda 3Q Net Profit Missed Y107.9B Expected in Poll of Analysts by Visible Alpha

29 de jan. de 2026, 06:33 UTC

Ganhos

Takeda Pharmaceutical 3Q Rev Y1.192T Vs. Y1.144T >4502.TO

29 de jan. de 2026, 06:32 UTC

Ganhos

Takeda Pharmaceutical 3Q Net Y103.6B Vs. Net Y23.8B >4502.TO

29 de jan. de 2026, 06:30 UTC

Ganhos

Takeda Pharmaceutical 9-Mos Net Y216.08B Vs Net Y211.08B

29 de jan. de 2026, 06:30 UTC

Ganhos

Takeda Pharmaceutical 9-Mos Pretax Pft Y312.67B Vs Pft Y282.38B

29 de jan. de 2026, 06:30 UTC

Ganhos

Takeda Pharmaceutical 9-Mos Oper Pft Y422.38B Vs Pft Y417.52B

29 de jan. de 2026, 06:30 UTC

Ganhos

Takeda Pharmaceutical 9-Mos Net Y216.08B Vs Net Y211.08B

29 de jan. de 2026, 06:30 UTC

Ganhos

Takeda Pharmaceutical 9-Mos Rev Y3.41T Vs Y3.53T

29 de jan. de 2026, 06:30 UTC

Ganhos

Takeda Pharmaceutical 9-Mos EPS Y137.31 Vs EPS Y133.71

30 de out. de 2025, 07:10 UTC

Ganhos

Takeda: 1H Core Business Results Were Consistent With Company's Expectations

30 de out. de 2025, 06:50 UTC

Ganhos

Takeda 2Q Net Loss Missed Y65.2B Profit Expected in Visible Alpha Poll of Analysts

30 de out. de 2025, 06:49 UTC

Ganhos

Takeda Pharmaceutical 2Q Rev Y1.113T Vs. Y1.176T >4502.TO

30 de out. de 2025, 06:48 UTC

Ganhos

Takeda Pharmaceutical 2Q Loss Y11.8B Vs. Net Y92.0B >4502.TO

Comparação entre Pares

Variação de preço

Takeda Pharmaceutical Co Ltd ADR Previsão

Preço-alvo

By TipRanks

39.72% parte superior

Previsão para 12 meses

Média 21 USD 39.72%

Máximo 21 USD

Mínimo 21 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para Takeda Pharmaceutical Co Ltd ADR - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

1 ratings

Comprar

Manter

Vender

Com base em 1 analistas que deram avaliações de ações para Takeda Pharmaceutical Co Ltd ADR - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.